PCM
PCRX icon

Peregrine Capital Management’s Pacira BioSciences PCRX Stock Holding History

Peregrine Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-184,695
Closed -$7.54M – 328
2023
Q1 		$7.54M Buy
184,695
+5,521
+3% +$220K 0.22% 205
2022
Q4 		$6.92M Buy
179,174
+28,712
+19% +$1.4M 0.22% 213
2022
Q3 		$8M Buy
150,462
+19,342
+15% +$1.08M 0.26% 182
2022
Q2 		$7.64M Sell
131,120
-109
-0.1% -$7.14K 0.23% 196
2022
Q1 		$10M Sell
131,229
-43,782
-25% -$2.92M 0.24% 178
2021
Q4 		$10.5M Buy
175,011
+20,071
+13% +$1.11M 0.21% 190
2021
Q3 		$8.68M Sell
154,940
-30,435
-16% -$1.75M 0.18% 224
2021
Q2 		$11.2M Sell
185,375
-8,250
-4% -$522K 0.2% 224
2021
Q1 		$13.6M Sell
193,625
-27,097
-12% -$1.94M 0.25% 202
2020
Q4 		$13.2M Sell
220,722
-19,974
-8% -$1.17M 0.25% 189
2020
Q3 		$14.5M Sell
240,696
-52,202
-18% -$3.03M 0.38% 99
2020
Q2 		$15.4M Sell
292,898
-42,621
-13% -$1.78M 0.44% 92
2020
Q1 		$11.3M Buy
335,519
+457
+0.1% +$19K 0.4% 107
2019
Q4 		$15.2M Sell
335,062
-3,902
-1% -$166K 0.39% 115
2019
Q3 		$12.9M Buy
338,964
+40,203
+13% +$1.6M 0.35% 124
2019
Q2 		$13M Buy
298,761
+56,733
+23% +$2.41M 0.32% 133
2019
Q1 		$9.21M Buy
242,028
+40,889
+20% +$1.6M 0.23% 161
2018
Q4 		$8.65M Sell
201,139
-23,608
-11% -$1.1M 0.24% 150
2018
Q3 		$11M Sell
224,747
-45,826
-17% -$1.98M 0.26% 150
2018
Q2 		$8.67M Sell
270,573
-55,483
-17% -$1.92M 0.22% 149
2018
Q1 		$10.2M Sell
326,056
-40,547
-11% -$1.44M 0.25% 146
2017
Q4 		$16.7M Sell
366,603
-37,538
-9% -$1.49M 0.39% 105
2017
Q3 		$15.2M Buy
404,141
+48,859
+14% +$1.97M 0.36% 111
2017
Q2 		$16.9M Sell
355,282
-1,014
-0.3% -$47K 0.42% 87
2017
Q1 		$17M Sell
356,296
-11,873
-3% -$513K 0.43% 86
2016
Q4 		$11.9M Buy
368,169
+6,239
+2% +$208K 0.31% 130
2016
Q3 		$12.4M Buy
+361,930
New +$14.2M 0.32% 129

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Peregrine Capital Management's PCRX Position: Q2 2023 in Review

Peregrine Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 184,695 shares — an estimated $7.54M sold.

Peregrine Capital Management first reported a position in PCRX in Q3 2016 and held it in 27 quarters. The position peaked at $17M in Q1 2017. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

  • Peregrine Capital Management reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
  • Peregrine Capital Management sold 184,695 Pacira BioSciences shares in Q2 2023, an estimated $7.54M.
  • Peregrine Capital Management first reported a position in Pacira BioSciences in Q3 2016 and held it in 27 quarters.
  • Peregrine Capital Management's Pacira BioSciences position peaked at $17M in Q1 2017.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Peregrine Capital Management's 13F filing for Q2 2023, filed 26 Jul 2023.